In January 2026, the FDA cleared something that had never been attempted in humans: a gene therapy designed not to fix a broken gene, but to reverse the aging process itself. The therapy, called ER-100, delivers three transcription factors into the eye to restore youthful epigenetic patterns in aging retinal cells. The company behind it is Life Biosciences, co-founded by Harvard geneticist David Sinclair — one of the most influential and controversial figures in longevity science.
This is not a supplement. It is not a wellness protocol. It is an AAV-delivered gene therapy entering a Phase 1 clinical trial (NCT07290244) — the first-ever human test of partial epigenetic reprogramming. If it works, it could mark the beginning of a new category of medicine: therapies that treat aging as a reversible condition rather than an inevitable decline.
The Founding Thesis
Life Biosciences was founded in 2017 in Boston by David Sinclair and Tristan Edwards, a former Goldman Sachs and Brevan Howard investment professional. The founding thesis was ambitious and unconventional: rather than targeting a single disease of aging, the company would attack aging itself by pursuing multiple biological hallmarks simultaneously.
The concept drew directly from Sinclair's decades of research at Harvard Medical School, where he directs the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging. His work on sirtuins (NAD+-dependent enzymes that regulate DNA repair and gene expression) and his Information Theory of Aging — the hypothesis that aging is primarily driven by the progressive loss of epigenetic information, not genetic mutations — provided the intellectual foundation.
Sinclair's core insight: if aging is "corrupted software" rather than "broken hardware," it should be reversible. Cells retain a backup copy of their youthful epigenetic state, and the right signal could restore it.
The Subsidiary Model (2017–2021)
Life Biosciences initially operated as a holding company with six subsidiaries, each targeting a different hallmark of aging:
- Iduna Therapeutics — Epigenetic reprogramming using Yamanaka factors (this would become the core of the company)
- Senolytic Therapeutics — Clearing senescent "zombie" cells to enable stem cell renewal
- Jumpstart Fertility — Restoring egg cell quality in women through NAD+ precursors
- Continuum Biosciences — Restoring metabolic function in aging cells by reducing free radical damage
- Animal Biosciences — Anti-aging compounds for pets (co-founded with Sinclair's brother Nick; later spun off independently)
- Spotlight Biosciences — Identifying novel peptides relevant to aging
The subsidiary model was unusual for biotech. The logic was portfolio diversification — pursue multiple approaches to aging and double down on whichever showed the most promise. By 2021, it became clear that one approach had pulled dramatically ahead.
The Science: Partial Epigenetic Reprogramming
The technology that defines Life Biosciences today emerged from a landmark 2020 paper in Nature (Lu et al., Nature 588, 124–129) from Sinclair's Harvard lab. The experiment was elegant:
The Setup: Mice with damaged optic nerves — mimicking the kind of age-related degeneration seen in glaucoma — received an AAV (adeno-associated virus) vector carrying three of the four Yamanaka factors: OCT4, SOX2, and KLF4 (collectively called "OSK"). The fourth factor, c-MYC, was deliberately omitted because of its well-established role in driving cancer.
The Result: The treated retinal ganglion cells regained youthful DNA methylation patterns. Axons regenerated. Vision was restored — not just stabilized, but actually reversed to a younger functional state. Crucially, the cells did not lose their identity (they remained retinal ganglion cells), and no tumors formed.
Why It Matters: This was the most compelling evidence to date that aging in living tissue is reversible through epigenetic reprogramming. The epigenome — the chemical tags on DNA and histones that tell each cell which genes to activate — had been "reset" to a younger state without converting the cells back into stem cells.
The mechanism requires TET DNA demethylases, enzymes that remove methyl groups from DNA. When TET enzymes were knocked out, the rejuvenation effect disappeared — confirming that the restoration of youthful methylation patterns was essential to the therapy's function.
The ICE Mouse Study (2023)
In January 2023, Sinclair's lab published a follow-up in Cell (Yang et al.) that provided even more direct evidence. They created the ICE (Inducible Changes to the Epigenome) mouse — an animal in which DNA double-strand breaks could be induced without mutating any coding genes. The breaks caused epigenetic chaos: the repair machinery scrambled chromatin marks, and the mice at 1 year old looked and behaved as if they were twice their age.
Key findings:
- DNA methylation analysis showed ICE cells were approximately 1.5 times "older" than control cells
- The genetic code was completely unaltered — only the epigenome was disturbed
- OSK expression reversed age-associated changes in gene expression
- Epigenetic age was reversed by up to 57% as measured by DNA methylation clocks
This was powerful evidence for the Information Theory of Aging: epigenetic noise alone — without any genetic mutations — is sufficient to cause aging, and that noise can be reversed.
Consolidation: From Holding Company to Clinical-Stage Biotech
Between 2021 and 2024, Life Biosciences consolidated around its most promising asset. Iduna Therapeutics was formally merged into the parent company in September 2021. The other subsidiaries were either wound down, spun off, or deprioritized. The company brought in experienced pharmaceutical leadership:
- Jerry McLaughlin — CEO (appointed 2021). Former President/CEO of Neos Therapeutics and AgeneBio. Involved in 12+ FDA-approved drugs over 30 years
- Dr. Mehmood Khan — Executive Chairman. Former PepsiCo Vice Chairman and CSO
- Dr. Sharon Rosenzweig-Lipson — Chief Scientific Officer. 30+ years in pharma R&D
- Dr. Michael Ringel — COO (appointed January 2026). Former BCG Managing Director/Senior Partner
- David Guyer, M.D. — Board member (appointed November 2025). Co-founder/CEO of EyeBio (Merck subsidiary); 30+ years in ophthalmology drug development
David Sinclair retained his role as Co-Founder and Chairman. The addition of Guyer to the board in late 2025 — an ophthalmology industry veteran — signaled that the company was serious about executing its eye disease programs.
The Pipeline
ER-100: First-in-Human Epigenetic Reprogramming (Phase 1)
ER-100 is an AAV-delivered gene therapy encoding the OSK transcription factors (OCT4, SOX2, KLF4). It is administered via intravitreal injection — a needle into the eye, the same route used for anti-VEGF therapies that millions of patients already receive.
The system includes a critical safety feature: doxycycline-inducible expression. The OSK genes are activated only when the patient takes the antibiotic doxycycline, giving clinicians a molecular "on/off switch" to control how long reprogramming occurs and to stop it if needed.
Trial Details (NCT07290244):
- Phase: Phase 1 (first-in-human)
- Indications: Open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION)
- Primary endpoints: Safety, tolerability, immune responses
- Secondary endpoints: Impact on visual acuity, visual field, retinal nerve fiber layer thickness, and other visual assessments
- Timeline: IND cleared January 28, 2026; enrollment began Q1 2026; results anticipated late 2026 or early 2027
- Significance: First-ever human trial of partial epigenetic reprogramming
Why the eye? The eye is an ideal first target for several reasons:
- It is an immune-privileged organ — the blood-retinal barrier limits immune reactions to injected vectors
- Intravitreal injection confines the therapy to the eye, reducing systemic exposure
- Visual function provides clear, measurable endpoints (visual acuity, visual field testing, OCT imaging)
- The 2020 Nature paper demonstrated proof of concept specifically in retinal ganglion cells
- Glaucoma affects 80+ million people worldwide — a massive unmet medical need
ER-300: Liver Disease Program (Preclinical)
Life Biosciences is also developing ER-300, a partial epigenetic reprogramming therapy for liver diseases including MASH (metabolic dysfunction-associated steatohepatitis, formerly NAFLD/NASH) and liver fibrosis. Preclinical data presented at the Aging Research & Drug Discovery (ARDD) conference in 2025 showed:
- Improved ALT and AST levels (liver damage markers)
- Improved cholesterol and bile acid profiles
- Reduced NAFLD activity scores
- Reduced hepatocyte lipid droplets (the fat accumulation that characterizes MASH)
The liver program is still in preclinical development, with no announced timeline for IND filing.
Future Expansion
In July 2025, Life Biosciences announced a research collaboration with SingHealth Duke-NUS REMEDIS in Singapore to explore applications of partial epigenetic reprogramming in additional aging-related diseases. This suggests the company is building a broader pipeline beyond ophthalmology and liver disease, though specific programs have not been disclosed.
Funding and Financial History
Life Biosciences has raised approximately $150–175 million across seven rounds from 14–16 investors. Notable rounds:
| Round | Date | Amount | Lead/Key Investors |
|---|---|---|---|
| Seed/Series A | 2017 | ~$25M | LeFrak, family trusts |
| Series B | January 2019 | $50M | LeFrak, Abundance Partners |
| Series C | January 2022 | $82M | Alpha Wave Ventures (Alpha Wave Global) |
| Grants (4 rounds) | Various | Various | Alzheimer's Drug Discovery Foundation |
The investor base is distinctive: Life Biosciences has been funded primarily by wealthy individuals and family offices (including the LeFrak family, prominent New York real estate developers), not traditional biotech venture capital firms. This may reflect the unconventional nature of the company's thesis — "reversing aging" was too speculative for many institutional biotech investors in 2017, though the landscape has shifted dramatically since then.
The company remains private with no announced IPO plans, though Forge Global lists it as a pre-IPO opportunity for secondary market investors.
The Competitive Landscape
Life Biosciences operates in one of the most closely watched — and most generously funded — areas of biotechnology. Several well-capitalized competitors are pursuing similar approaches to epigenetic reprogramming:
| Company | Funding | Approach | Clinical Status |
|---|---|---|---|
| Life Biosciences | ~$150–175M | AAV-delivered OSK (partial reprogramming) | Phase 1 (first in humans) |
| Altos Labs | ~$3B+ | Cellular reprogramming; recruited Yamanaka himself | Preclinical |
| Retro Biosciences | $180M (Sam Altman) | HSC reprogramming, autophagy, plasma-inspired therapeutics | Preclinical |
| Turn Biotechnologies | ~$60M+ | mRNA-based Epigenetic Reprogramming of Aging (ERA) | Preclinical |
| NewLimit | $40M+ (Brian Armstrong) | Epigenetic reprogramming for immune rejuvenation | Preclinical |
| Calico Labs | ~$1.5B+ (Google/Alphabet) | Broad aging biology research | Long-term research |
| Unity Biotechnology | Public (NASDAQ: UBX) | Senolytics (different mechanism) | Clinical stage |
Life Biosciences' key competitive advantage is simple but profound: it is the first company in the world to reach human clinical trials with an epigenetic reprogramming therapy. Despite having a fraction of the funding of Altos Labs, Life Biosciences got to the clinic first — a testament to the strength of the underlying Harvard data and the company's focused execution.
The mRNA approach used by Turn Biotechnologies offers a potential advantage in that mRNA is transient (it degrades naturally), avoiding the permanent integration concerns of AAV vectors. However, Turn has not yet advanced to clinical trials.
Altos Labs, despite its enormous war chest and the involvement of Shinya Yamanaka (the Nobel laureate who discovered the reprogramming factors), remains in preclinical stages. The company has been hiring aggressively but has not announced a clinical timeline.
Controversies and Risks
Scientific Controversy
David Sinclair is a polarizing figure in the scientific community. While his 2020 Nature paper on OSK-mediated vision restoration has been well-received, other aspects of his work have drawn criticism:
- The 2023 Cell retraction: A paper claiming age reversal across multiple tissues using a chemical cocktail was retracted due to data integrity concerns, though this was a different program from the ER-100 gene therapy
- Academy resignation (March 2024): Sinclair stepped down as president of the Academy for Health and Lifespan Research after claiming on social media that his gene therapy had "reversed aging" in monkeys, and after a separate controversy involving his brother's pet supplement company, Animal Biosciences. Fellow scientists, including Dr. Matt Kaeberlein, criticized the claims as unsupported
- The NMN controversy: MetroBiotech, another Sinclair-cofounded company, successfully lobbied the FDA to reclassify NMN (a popular NAD+ supplement) as an investigational drug, effectively pulling it from the supplement market — a decision that angered consumers and raised conflict-of-interest concerns
Technical Risks
Any gene therapy entering Phase 1 faces substantial risks:
- Immune response to AAV vectors — the most common adverse event in AAV gene therapy trials historically
- Durability of reprogramming — it is unknown how long a single treatment will maintain its rejuvenating effect, or whether repeated doses will be needed
- Safety of prolonged OSK expression — even without c-MYC, there are theoretical concerns about uncontrolled cell proliferation. The doxycycline-inducible system mitigates this, but long-term safety data will take years to accumulate
- Translation from mice to humans — many therapies that work in animal models fail in human trials. The non-human primate data is encouraging but limited
Regulatory Risks
Epigenetic reprogramming is an entirely new therapeutic category. Regulators have no precedent for evaluating therapies that claim to reverse biological aging. The FDA's willingness to clear the IND was a positive signal, but the regulatory path forward — particularly for broader indications beyond ophthalmology — remains uncharted.
What Success Would Mean
If ER-100 demonstrates safety and early efficacy signals in Phase 1, the implications extend far beyond glaucoma treatment. It would provide proof-of-concept that epigenetic reprogramming can safely reverse aging in human tissue — validating a theoretical framework that has been debated for over a decade.
The eye is a starting point. Sinclair and the Life Biosciences team have repeatedly stated that the platform is designed to be extensible to other organs and tissues. The liver program (ER-300) is already in preclinical development. If the core technology works, applications in neurodegeneration, cardiovascular disease, musculoskeletal aging, and organ regeneration become plausible.
At the World Government Summit in Dubai in February 2026, Sinclair declared that "ageing could soon be reversible" and predicted age-reversing treatments could be available within 10 years. Whether that timeline proves realistic remains to be seen. But for the first time, the hypothesis that aging is reversible is being tested where it matters most — in human patients.
The Bottom Line
Life Biosciences is not the best-funded company in the longevity space. It does not have the star-studded roster of Altos Labs or the Silicon Valley backing of Retro Biosciences. What it has is something more valuable at this stage: a therapy in human clinical trials. ER-100 represents the culmination of two decades of research from David Sinclair's Harvard lab, channeled into an AAV gene therapy that uses three Yamanaka factors to restore youthful epigenetic patterns in aging tissue.
The results of the Phase 1 trial, expected by late 2026 or early 2027, will be among the most closely watched in all of medicine. If partial epigenetic reprogramming proves safe and shows signs of efficacy in human patients, it will not just advance one company's pipeline — it will open an entirely new frontier in how we understand and treat aging.
Sources & Further Reading
- Lu, Y. et al. "Reprogramming to recover youthful epigenetic information and restore vision." Nature 588, 124–129 (2020). doi:10.1038/s41586-020-2975-4
- Yang, J.-H. et al. "Loss of epigenetic information as a cause of mammalian aging." Cell 186, 305–326 (2023). doi:10.1016/j.cell.2022.12.027
- Life Biosciences — FDA IND Clearance Announcement (January 2026)
- ClinicalTrials.gov — NCT07290244 (Phase 1 ER-100 trial)
- Life Biosciences — ARDD 2025 Preclinical Data
- MIT Technology Review — First Human Test of Rejuvenation (January 2026)
- Nature Biotechnology — FDA Go-Ahead for Age Reversal Trial (2026)
- Fortune — First Partial De-Aging Human Trial (January 2026)
- Sinclair, D.A. & LaPlante, M.D. Lifespan: Why We Age — and Why We Don't Have To. Atria Books (2019).
Last updated: March 2026.
